Myristoyl Pentapeptide-17 (MPP-17) is a myristoylated cosmetic peptide used at low dose in leave-on lash and brow products. This guide covers the practical steps of working with MPP-17 powder: confirming the exact supplied form, calculating the correct active content, choosing a delivery approach and building a stable, eye-tolerant finished formula. Specific temperatures, pH targets and use levels must come from the supplier's confirmed TDS and COA for the exact material; generic peptide-processing rules should not be substituted.
Confirm the Exact Raw-Material Form
Before any formulation work, confirm what the supplied powder actually is. Myristoyl Pentapeptide-17 is commonly identified by the target structure Myr-Lys-Leu-Ala-Lys-Lys-NH2 (Myr-KLAKK-NH2), which contains a C-terminal amide. Commercial peptide powders may also contain counter-ions such as acetate, depending on the manufacturing and purification process. Buyers should therefore distinguish peptide sequence and terminal structure from counter-ion status and confirm both on the batch-specific documentation.
Check on the batch-specific COA and TDS:
- Peptide sequence and C-terminal structure
- Counter-ion type and content, where applicable
- HPLC purity
- Peptide assay / active content
- Water content
- Molecular-weight / MS identity confirmation
- Residual solvents
- Microbiological specification
The identity step is the most important part of MPP-17 formulation. If the peptide identity, terminal form or assay basis is not stated, ask the supplier for the documentation before ordering or scaling up.
The supplied form matters for more than paperwork. A free peptide and its acetate salt can differ in solubility behavior, hygroscopicity and the weight of peptide delivered per gram of material, which in turn affects both the dosing calculation and the finished formula's behavior. Confirming the identity first prevents errors that are difficult to fix later in the workflow.

Why HPLC Purity Is Not the Same as Active Peptide Content
HPLC area purity and active peptide content (assay) describe different attributes and should not be treated as interchangeable values. HPLC purity reflects the relative chromatographic purity of the peptide peak, while assay or peptide content is used to determine the amount of active peptide present in the supplied material.
For quantitative dosing, formulators should use the supplier's confirmed active-content or assay basis rather than assuming that HPLC area purity represents the active fraction.
Required raw material = Target active peptide amount ÷ Actual peptide fraction
For example (illustrative only - use the assay from the confirmed COA): if a development batch requires 10 mg of active peptide and the supplied powder has an assay of 85%, approximately 11.76 mg of raw material would be required.
Powder vs Premixed Solution
Powder: suitable for manufacturers with formulation and precision-weighing capabilities. It offers greater flexibility in active concentration and formulation design, but requires accurate control of peptide content and dosing.
Premixed solution: easier for small-batch prototyping, because the peptide arrives in a defined vehicle. The trade-off is that the active concentration is fixed by the supplier, and the buyer must confirm the actual active peptide content rather than dosing by total solution weight.
Whenever comparing powder and solution, compare on an active-peptide basis - not on price or weight per kilogram of supplied material.
For development-stage quantities, a practical approach is to evaluate the exact supplied material in the intended vehicle before scaling: confirm dissolution, appearance and short-term stability in a small batch, then lock the process parameters from the supplier's TDS for scale-up.
Suitable Product Formats
MPP-17 fits leave-on, low-dose formats where the formula has extended contact with the lash line and brow area:
- Water-based lash serum
- Eyebrow serum
- Gel serum
- Mascara primer
- Precision-brush treatment
Rinse-off formats are less natural for this ingredient class, because the shorter contact time of a wash-off product should be considered when determining active concentration, formulation design and intended cosmetic positioning.
Suggested Manufacturing Workflow
A typical workflow for an MPP-17 lash or brow serum:
- Verify the COA and TDS for the exact batch
- Calculate the required raw-material weight from the peptide assay
- Prepare a suitable stock or pre-solution
- Add under the supplier's stated processing-temperature conditions
- Adjust the final pH to the target range
- Complete appearance, content and microbiological testing
- Run accelerated and real-time stability testing plus packaging compatibility
Specific temperatures, pH targets, addition order and use levels must come from the supplier's confirmed TDS and COA for the exact supplied material - not from a generic peptide rule or another supplier's data.
Keep batch documentation for each production run, including the COA reference, calculated addition weight and analytical results, so that any deviation can be traced.
Eye-Area Formulation Considerations
Lash and brow products are applied close to the eye, so the formula should be designed with eye tolerance in mind from the start. Key variables to screen include:
- Fragrance and essential oils
- Alcohol content
- Preservative system
- Surfactants
- Osmolarity
- Final pH
- Behavior on accidental eye exposure
- Applicator hygiene and repeated use
Compatibility and tolerance should be verified experimentally for the exact MPP-17 material and the intended finished formula rather than inferred from peptide chemistry alone. Eye-area products also benefit from clear instructions on application and on stopping use if irritation occurs.
Because lash serums are applied close to the eye, osmolarity, final pH and the overall irritation potential of the finished formula should be evaluated during product development. Tolerance should be established from the complete finished product rather than inferred from the peptide alone.
Compatibility With Other Lash-Serum Ingredients
MPP-17 is frequently combined with other conditioning ingredients in commercial formulas, including Myristoyl Hexapeptide-16, Biotinoyl Tripeptide-1, panthenol, hyaluronic acid, amino acids, glycerin and selected botanical extracts. Such combinations are common in the category, but compatibility should not be assumed without testing.
Electrolytes, extreme pH, oxidation-sensitive actives and certain preservative or fragrance systems can all influence peptide stability and finished-product appearance. Screen the full formula rather than testing the peptide in isolation, and verify compatibility for the exact supplied material and target product.
Stability and Packaging
Potential stability risks should be evaluated for the exact supplied MPP-17 material and finished formula. Depending on peptide identity, carrier system and packaging, relevant studies may include light exposure, oxidative stability, temperature cycling, freeze-thaw behavior and container compatibility. Packaging selection should therefore be based on stability data rather than on peptide category alone.
For lash and brow serums, practical packaging considerations include airless or fine-tip applicator systems, protection from light, minimizing contamination on repeated opening, and monitoring for peptide adsorption to pump parts and polymers. A microbial challenge test is advisable for aqueous eye-area formulas, and accelerated stability testing should be supported by real-time data before launch.
Real-time stability data at the intended storage condition should be reviewed before launch, since accelerated data alone may not reflect the full behavior of a low-dose aqueous formula.

Common Formulation Problems
| Problem | Possible Cause | Where to Look |
|---|---|---|
| Powder does not dissolve fully | Concentration, salt form or solvent mismatch | Recheck TDS and stock-solution method |
| Cloudy finished product | pH, electrolyte or fragrance interaction | Run compatibility screening |
| Peptide content drops over time | Temperature, oxidation or storage issue | Investigate with HPLC stability testing |
| Eye-area irritation | Preservative, fragrance or overall formula | Evaluate the complete finished product |
| Batch-to-batch inconsistency | Dosing by HPLC purity instead of assay | Calculate from the actual peptide assay |
FAQ
Is Myristoyl Pentapeptide-17 powder water-soluble?
Solubility depends on the supplied form, salt type and vehicle. Confirm the recommended dissolution approach and carrier in the supplier's TDS rather than assuming generic peptide solubility behavior.
What phase should it be added to?
The addition point depends on the exact supplied material, solvent system and finished formula. Follow the supplier's confirmed TDS for recommended incorporation phase, processing temperature and mixing conditions rather than applying a generic peptide-processing rule.
Can it be heated?
Processing temperature limits should be taken from the supplier's confirmed TDS for the exact material. Avoid unnecessary heat unless compatibility has been established.
How is its active content calculated?
Use the assay or peptide-content basis from the batch COA: required raw material = target active peptide ÷ actual peptide fraction. HPLC area purity alone should not be used for dosing.
What tests are required for a lash serum?
At a minimum: appearance, content, microbiological specification, preservative challenge, accelerated and real-time stability, and packaging compatibility. Eye-area formulas should also include tolerance assessment of the finished product.
References
- PubChem CID 127264611 - Myristoyl Pentapeptide-17. National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/127264611
- Danish Environmental Protection Agency. Survey and risk assessment of eyelash and eyebrow serums. 2025. https://www2.mst.dk/Udgiv/publications/2025/05/978-87-7038-999-0a.pdf
- Eyelash serums: A comprehensive review. Journal of Cosmetic Dermatology. 2024. https://onlinelibrary.wiley.com/doi/full/10.1111/jocd.16278





